Human serum albumin in formulations

Abstract

To provide improved methods to reduce or prevent the formation of fatty acid particles in protein formulations and protein formulations that have reduced levels of fatty acid particles.SOLUTION: A method of preventing or reducing formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation capable of forming fatty acid particles. The formulation capable of forming fatty acid particles includes a polysorbate.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] Field The present invention relates generally to methods for removing, reducing, or preventing the formation of fatty acid particles in drug formulations. [Background technology]

[0002] background There are many challenges in designing a drug formulation to improve its manufacturing, storage, handling, and administration characteristics while minimizing undesirable side effects. For example, formulation development seeks to identify solution conditions and additives or excipients that can increase stability and reduce the occurrence of chemical or physical changes that often result in aggregation and subsequently lead to an increase in sub-visible or visible particles.

[0003] The prevention and reduction of particle formation in formulated injectable drug products is particularly challenging and has been the focus of discussion and research within the pharmaceutical industry for several years. Visible or even invisible particles, composed of synthetic or biological materials and originating from various sources, can increase the possibility of immunogenicity in patients and can have various effects on the quality of drug products. One such possible impurity can be fatty acid particles formed during manufacturing, shipping, storage, handling, or administration. Fatty acid particles can cause adverse immunogenic effects and affect shelf life.

[0004] It should be appreciated that a need exists for improved methods for reducing or preventing the formation of fatty acid particles in protein formulations, and for protein formulations having reduced levels of fatty acid particles. Summary of the Invention

[0005] overview Maintaining the stability of drug formulations during storage as well as during manufacture, shipping, handling, and administration is a major challenge. Among drug products, protein biologics have gained popularity due to their success and versatility. Therapeutic proteins are the fastest growing class of drugs, accounting for approximately one-third of the drug market. One of the major challenges in protein biologics development is overcoming the limited stability of proteins that can be affected by the presence of visible and sub-visible particles. This is due to growing concerns over the potential immunogenicity of particles, both proteinaceous and non-proteinaceous. Mitigation of the formation of such particles can be a critical step in the development of drug formulations. An example of one challenge is preventing or reducing the formation of fatty acid particles in the formulation.

[0006] The present disclosure provides methods for preventing or reducing the formation of fatty acid particles in a formulation.

[0007] In one exemplary embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles.

[0008] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may comprise adding an effective amount of human serum albumin to a formulation that may form fatty acid particles.

[0009] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, and the formulation that may form fatty acid particles may include a polysorbate.

[0010] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, where the formulation that may form fatty acid particles comprises a polysorbate selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and combinations thereof.

[0011] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, wherein the formulation that may form fatty acid particles comprises from about 0.001% w / v to about 1% w / v of polysorbate.

[0012] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, the formulation comprising a polysorbate and at least one protein.

[0013] In one aspect of this embodiment, a method for preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, the formulation including a polysorbate and an antibody.

[0014] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may comprise adding human serum albumin to a formulation which may form fatty acid particles, the fatty acid particles comprising free fatty acids.

[0015] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, the fatty acid particles comprising free fatty acids, and the ratio of molecules of free fatty acid to molecules of human serum albumin may be from about 6:1 to about 1:1.

[0016] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may comprise adding human serum albumin to a formulation that may form fatty acid particles, the fatty acid particles comprising a free fatty acid selected from the group consisting of oleic acid, palmitic acid, stearic acid, myristic acid, lauric acid, and combinations thereof.

[0017] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, and the formulation may contain at least about 5.5 mg / mL human serum albumin.

[0018] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, and the formulation may be a parenteral formulation.

[0019] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, the fatty acid particles being visible or sub-visible.

[0020] In one aspect of this embodiment, a method of preventing or reducing the formation of fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, and the fatty acid particles may be detectable by Raman spectroscopy.

[0021] The present disclosure provides, at least in part, a method for solubilizing fatty acid particles in a formulation.

[0022] In one exemplary embodiment, a method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles.

[0023] In one aspect of this embodiment, a method of solubilizing fatty acid particles in a formulation may include adding an effective amount of human serum albumin to a formulation that may form fatty acid particles.

[0024] In one aspect of this embodiment, the method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation capable of forming fatty acid particles, and the formulation capable of forming fatty acid particles may include a polysorbate.

[0025] In one aspect of this embodiment, the method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation capable of forming fatty acid particles, and the formulation capable of forming fatty acid particles may include a polysorbate selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and combinations thereof.

[0026] In one aspect of this embodiment, the method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation capable of forming fatty acid particles, and the formulation capable of forming fatty acid particles may include about 0.001% w / v to about 1% w / v polysorbate.

[0027] In one aspect of this embodiment, the method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation capable of forming fatty acid particles, and the formulation capable of forming fatty acid particles may include a polysorbate and at least one protein.

[0028] In one aspect of this embodiment, the method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation capable of forming fatty acid particles, the formulation comprising a polysorbate and an antibody.

[0029] In one aspect of this embodiment, a method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, and the fatty acid particles may include free fatty acids.

[0030] In one aspect of this embodiment, a method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation capable of forming fatty acid particles, the fatty acid particles may include free fatty acids, and the ratio of molecules of free fatty acid to molecules of human serum albumin may be from about 6:1 to about 1:1.

[0031] In one aspect of this embodiment, a method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, and the fatty acid particles may include a free fatty acid selected from the group consisting of oleic acid, palmitic acid, stearic acid, myristic acid, lauric acid, and combinations thereof.

[0032] In one aspect of this embodiment, a method of solubilizing fatty acid particles in a formulation may include adding at least about 5.5 mg / mL of human serum albumin to a formulation that may form fatty acid particles.

[0033] In one aspect of this embodiment, the method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, and the formulation may be a parenteral formulation.

[0034] In one aspect of this embodiment, a method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to the formulation which may form fatty acid particles, the fatty acid particles being visible or sub-visible.

[0035] In one aspect of this embodiment, a method of solubilizing fatty acid particles in a formulation may include adding human serum albumin to a formulation that may form fatty acid particles, the fatty acid particles being detectable by Raman spectroscopy.

[0036] The disclosure provides, at least in part, a formulation that includes (i) an active agent and (ii) human serum albumin.

[0037] In one exemplary embodiment, the formulation may include (i) an active agent, (ii) human serum albumin, and (iii) a polysorbate.

[0038] In one aspect of this embodiment, the formulation may include (i) an antibody, (ii) human serum albumin, and (iii) a polysorbate.

[0039] In one aspect of this embodiment, the formulation may include (i) an active agent, (ii) human serum albumin, and (iii) a polysorbate selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a combination thereof.

[0040] In one aspect of this embodiment, the formulation may include (i) an antibody, (ii) human serum albumin, and (iii) a polysorbate, and the formulation may be administered by a parenteral route.

[0041] In one aspect of this embodiment, the formulation may include (i) an antibody, (ii) human serum albumin, (iii) a polysorbate, and (iv) a lipase enzyme.

[0042] In one aspect of this embodiment, the formulation may comprise: (i) an active agent; and (ii) at least about 5.5 mg / mL human serum albumin.

[0043] In one aspect of this embodiment, the formulation may include: (i) an active agent; (ii) at least about 5.5 mg / mL human serum albumin; and (iii) about 0.001% w / v to about 1% w / v polysorbate.

[0044] In one aspect of this embodiment, the formulation may include (i) an active agent, (ii) human serum albumin, and (iii) a polysorbate, and the formulation may further include fatty acid particles having free fatty acids, and the ratio of molecules of free fatty acid to molecules of human serum albumin may be from about 6:1 to about 1:1.

[0045] In one aspect of this embodiment, the formulation may include (i) an antibody, (ii) human serum albumin, and (iii) a polysorbate, which may degrade to form fatty acid particles.

[0046] In one aspect of this embodiment, the formulation may include (i) an antibody, (ii) human serum albumin, (iii) a polysorbate, and (iv) a lipase enzyme, where the lipase enzyme may hydrolyze the polysorbate to form fatty acid particles.

[0047] In one aspect of this embodiment, the formulation may comprise (i) an antibody, (ii) human serum albumin, and (iii) a polysorbate, and the formulation may further comprise fatty acid particles.

[0048] In one aspect of this embodiment, the formulation may comprise (i) an antibody, (ii) human serum albumin, and (iii) a polysorbate, and the formulation may further comprise fatty acid particles comprising free fatty acids.

[0049] In one aspect of this embodiment, the formulation may include (i) an antibody, (ii) human serum albumin, and (iii) a polysorbate, and the formulation may further include fatty acid particles comprising an aliphatic fatty acid having from about 6 to about 22 carbons.

[0050] In one aspect of this embodiment, the formulation may comprise (i) an antibody, (ii) human serum albumin, and (iii) a polysorbate, and the formulation may further comprise fatty acid particles comprising oleic acid.

[0051] In one aspect of this embodiment, the formulation may comprise (i) an antibody, (ii) human serum albumin, and (iii) a polysorbate, and the formulation may further comprise fatty acid particles comprising a free fatty acid selected from oleic acid, palmitic acid, stearic acid, myristic acid, lauric acid, and combinations thereof.

[0052] These and other aspects of the present invention will be better appreciated and understood when considered in conjunction with the following description and the accompanying drawings. The following description, while setting forth various embodiments and numerous specific details thereof, is given by way of illustration and not limitation. Many substitutions, modifications, additions, or rearrangements may be made within the scope of the invention. [Brief description of the drawings]

[0053] [Figure 1] 1 shows a plot of absorbance at 450 nm as a function of time of lipase concentration to assess the ability of Chromobacterium viscosum lipase to generate fatty acid particles by facilitating the degradation of PS80, according to an exemplary embodiment. [Diagram 2] 1 shows a plot of Raman intensity (au) as a function of Raman shift (1 / cm) to identify the composition of fatty acid-based particles prepared according to an exemplary embodiment. [Diagram 3] 1 shows a plot of absorbance at 450 nm as a function of time for various concentrations of FAF-HSA added to a polysorbate-containing solution prepared according to an exemplary embodiment. [Figure 4] 1 shows a plot of absorbance at 450 nm as a function of time for various SA-HSA concentrations added to polysorbate-containing solutions prepared according to exemplary embodiments. [Diagram 5] 1 shows a plot of absorbance at 450 nm as a function of time for various polyclonal IgG concentrations without added HSA. [Figure 6]1 shows plots of absorbance at 450 nm as a function of time for formulations containing a monoclonal antibody that are non-lyophilized (Panel A) and lyophilized (Panel B). [Figure 7] 1 shows plots of absorbance at 450 nm as a function of time upon addition of 4.5 mg / mL FAF-HSA (panel A) and 7.5 mg / mL FAF-HSA (panel B) to various polyclonal IgG concentrations, according to an exemplary embodiment. [Figure 8] 1 shows a plot of absorbance at 450 nm as a function of time for various serum concentrations added to preformed fatty acid particles, according to an exemplary embodiment. [Figure 9] 1 shows a plot of absorbance at 450 nm as a function of time for a formulation containing human serum and preformed free fatty acid particles in solution. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0054] Detailed Description Among drug products, protein-based biologics are an important class of drugs that offer high levels of selectivity, potency, and efficacy, as evidenced by the considerable increase in clinical trials over the past few years with monoclonal antibodies (mAbs). Introducing a protein-based biologic into the clinic can be a multi-year endeavor that requires coordinated efforts across various research and development disciplines, including discovery, process and formulation development, analytical characterization, and preclinical toxicology and pharmacology. One important aspect of a clinically and commercially viable biologic is the stability of the drug product in terms of the manufacturing process as well as shelf life. As with many purified proteins, the stability of the native conformation of mAbs is relatively small, typically on the order of 20-25 kcal / mol (Kristi L. Lazar, Thomas W. Patapoff & Vikas K. Sharma, Cold denaturation of monoclonal antibodies, 2 MABS 42-52 (2010)). This often requires appropriate steps to help improve the physical and chemical stability of mAbs through the different solution conditions and environments required for manufacturing and storage with minimal impact on product quality, including identification of molecules with higher inherent stability, protein engineering, and formulation development. Formulation development seeks to identify solution conditions and additives or excipients that will increase mAb stability and reduce the occurrence of chemical or physical changes that can often result in aggregation and subsequent increases in sub- or visible particles.

[0055] Visible and sub-visible particles, especially in formulated drug products, have been the focus of discussion and investigation within the pharmaceutical industry for several years and may raise quality concerns. Particles composed of synthetic or biological materials and derived from various sources may increase the possibility of immunogenic effects in patients (S. Bukofzer et al., Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products, 69 PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY 123-139 (2015); SELangille, Particulate Matter in Injectable Drug Products, 67 PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY 186-200 (2013)) and may have various effects on drug products. There may be several causes for the formation of visible and sub-visible particles in formulations, which may include proteinaceous and non-proteinaceous particles. Such particles may lead to increased concerns regarding potential immunogenicity. The United States Pharmacopeia (USP) and the European Pharmacopeia (Ph.Eur.) currently define concentration limits in parenteral solutions only for particles larger than 10 μm, and regulatory agencies increasingly expect quantitative characterization of micron particles between 1 and 10 μm, and qualitative characterization of submicron particles between 100 nm and 1000 nm, which are already in the early development phase (USP <788> .In:The United States Pharmacopoeia,National Formulary.2009;Ph.Eur.2.9.19).

[0056] Visible and sub-visible particles in drug formulations may be related to free fatty acid content and subsequent fatty acid particle formation. Free fatty acids and associated fatty acid particle formation may occur in protein formulations containing polysorbates. More than 70% of commercially available monoclonal antibody therapeutics contain 0.001%-0.1% polysorbate to protect proteins from interfacial stresses such as adsorption and aggregation. Many preparations of polysorbates contain a mixture of various fatty acid chains, e.g., polysorbate 80 contains oleic, palmitic, myristic, and stearic fatty acids, with the monooleic acid fraction making up approximately 58% of the polydisperse mixture (Nitin Dixit et al., Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles, 105 JOURNAL OF PHARMACEUTICAL SCIENCES 1657-1666 (2016)). Polysorbates are prone to autoxidation in a pH- and temperature-dependent manner, and in addition, exposure to UV light can result in instability (Ravuri SkKishore et al., Degradation of Polysorbates 20 and 80: Studies on Thermal Autoxidation and Hydrolysis, 100 JOURNAL OF PHARMACEUTICAL SCIENCES 721-731(2011)), resulting in free fatty acids in solution with sorbitan head groups. Thus, polysorbates can contribute to particle formation by autoxidation and hydrolysis, resulting in free fatty acids and subsequent fatty acid particle formation.Hydrolysis of polysorbates by various host cell proteins, such as phospholipase B-like 2 (PLBL2) and lipoprotein lipase (Josephine Chiu et al., Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations, 114 BIOTECHNOLOGY AND BIOENGINEERING 1006-1015(2016)), can generate free fatty acids under certain conditions (Nitin Dixit et al., Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles, 105 JOURNAL OF PHARMACEUTICAL SCIENCES 1657-1666(2016)).These free fatty acids, as well as long chain fatty acids (especially stearates, oleates, palmitates) resulting from the degradation of PS20 precipitate due to its low solubility (Nidhi Doshi, Barthelemy Demeule & Sandeep Yadav, Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations, 12 MOLECULAR PHARMACEUTICS 3792-3804 (2015); Steven R. Labrenz, Ester Hydrolysis of Polysorbate 80 in mAb Drug Product: Evidence in Support of the Hypothesized Risk After the Observation of Visible Particulate in mAb Formulations, 103 JOURNAL OF PHARMACEUTICAL SCIENCES 2268-2277 (2014)), could potentially lead to fatty acid particle formation in the drug in the current model.

[0057] Several reports have detailed the presence of visible and subvisible particles in drug products containing either polysorbate 20 or polysorbate 80 (Xiaolin Cao et al., Free Fatty Acid Particles in Protein Formulations, Part 1: Microspectroscopic Identification, 104 JOURNAL OF PHARMACEUTICAL SCIENCES 433-446(2015); Christine C. Siska et al., Free Fatty Acid Particles in Protein Formulations, Part 2: Contribution of Polysorbate Raw Material, 104 JOURNAL OF PHARMACEUTICAL SCIENCES 447-456(2015); Nidhi Doshi, Barthelemy Demeule & Sandeep Yadav, Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations, 12 MOLECULAR PHARMACEUTICS 3792-3804(2015), Nitin Dixit et al.,Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles,105 JOURNAL OF PHARMACEUTICAL SCIENCES1657-1666(2016), Anthony Tomlinson et al.,Polysorbates 20 and 80 Degradation by Group XV Lysosomal Phospholipase A 2 Isomer X1 in Monoclonal Antibody Formulations,105 JOURNAL OF PHARMACEUTICAL SCIENCES 1633-1642(2016)). Particles characterized by spectroscopy and shown to be composed of fatty acids (Nidhi Doshi, Barthelemy Demeule & Sandeep Yadav, Understanding Particle Formation: Solubility of Free Fatty Acids as Polysorbate 20 Degradation Byproducts in Therapeutic Monoclonal Antibody Formulations, 12 MOLECULAR PHARMACEUTICS 3792-3804 (2015), Anthony Tomlinson et al., Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism, 12 MOLECULAR PHARMACEUTICS 3805-3815 (2015)), and pure proteins (Xiaolin Cao et al.,Free Fatty Acid Particles in Protein Formulations,Part 1:Microspectroscopic Identification,104 JOURNAL OF PHARMACEUTICAL SCIENCES 433-446(2015)), or a mixture of fatty acids and proteins, suggested that hydrolysis of polysorbates may directly contribute to the appearance of particles in formulated drug products. Host cell proteins, specifically lipases, were cited as possible root causes (Nitin Dixit et al.,Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles,105 JOURNAL OF PHARMACEUTICAL SCIENCES1657-1666(2016)). Thus, although the current United States Pharmacopeia (USP) standard is <100 ppm residual host cell protein (Catalin Doneanu et al., Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography / mass spectrometry, 4 MABS 24-44(2012)), the presence of minute levels of host cell lipases may result in polysorbate hydrolysis and release of free long-chain fatty acids. Furthermore, the particle content standard set by the USP places a limit of 6000 particles / container for sizes above 10 μM and 600 particles / container for sizes above 25 μM (USP General Chapter 788, Particulate Matter in Injections), suggesting that the presence of host cell lipases may affect shelf life (S. Bukofzer et al.,Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products,69 PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY 123-139(2015)). .

[0058] The overall homogeneity of polysorbate preparations and the inherent long-term stability of polysorbate may cause problems with free fatty acid content.Although the safety and efficacy of drug products containing fatty acid particles have not been fully evaluated, it is clearly advantageous to avoid possible quality concerns.Whether fatty acid particles cause immunogenic responses in patients is still unknown, but fine particles in drug products are generally considered undesirable.

[0059] In the absence of known methods to mitigate the formation of fatty acid particles or to rapidly and completely solubilize preformed particles, effective and efficient methods and formulations have been developed, as disclosed herein. Also disclosed is an experimental system for the rapid production of fatty acid particles, and the novel use of human serum albumin in the context of biopharmaceutical formulations.

[0060] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing, certain methods and materials are described herein. All publications mentioned are incorporated herein by reference.

[0061] The term "a" should be understood to mean "at least one," and the terms "about" and "approximately" should be understood to allow for standard variations as understood by one of ordinary skill in the art, and when ranges are provided, the endpoints are included.

[0062] Because the presence of fatty acid particles in biologics can be of substantial concern across the industry, from companies to regulators, providers, and patients, methods of preventing and / or reducing the formation of such fatty acid particles, and formulations that can reduce the levels of such fatty acid particles, and / or methods of preventing the formation of such fatty acid particles, are important in drug product development.

[0063] In some exemplary embodiments, the present disclosure provides formulations that include an active agent and that can reduce the level of and / or prevent the formation of fatty acid particles.

[0064] As used herein, the term "formulation" refers to an active agent formulated together with one or more pharma- ceutically acceptable vehicles.

[0065] As used herein, the term "active agent" can include biologically active ingredients of a drug product. An active agent can refer to any substance or combination of substances used in a drug product that is intended to provide pharmacological activity or otherwise have a direct effect on the diagnosis, cure, mitigation, treatment, or prevention of disease, or to have a direct effect on the restoration, correction, or alteration of the physiology of an animal. Non-limiting methods for preparing active agents can include using fermentation processes, recombinant DNA, isolation and recovery from natural sources, chemical synthesis, or combinations thereof.

[0066] In some exemplary embodiments, the active agent may be a protein.

[0067] As used herein, the term "protein" can include any amino acid polymer with covalently linked amide bonds. A protein includes one or more amino acid polymer chains, commonly known in the art as "polypeptides." A "polypeptide" refers to a polymer consisting of amino acid residues, related naturally occurring structural variants, and synthetic non-natural analogs thereof linked via peptide bonds, related naturally occurring structural variants, and synthetic non-natural analogs thereof. A "synthetic peptide or polypeptide" refers to a non-natural peptide or polypeptide. A synthetic peptide or polypeptide can be synthesized, for example, using an automated polypeptide synthesizer. A variety of solid-phase peptide synthesis methods are known to those skilled in the art. A protein may contain one or more polypeptides to form a single functional biomolecule. Proteins can include any of biopharmaceutical proteins, recombinant proteins used in research or therapy, trap proteins and other chimeric receptor Fc fusion proteins, chimeric proteins, antibodies, monoclonal antibodies, polyclonal antibodies, human antibodies, and bispecific antibodies. In another exemplary embodiment, a protein can include antibody fragments, nanobodies, recombinant antibody chimeras, cytokines, chemokines, peptide hormones, and the like. Proteins can be produced using recombinant cell-based production systems such as the insect baculovirus system, yeast systems (e.g., Pichia species), mammalian systems (e.g., CHO cells and CHO derivatives such as CHO-K1 cells).For a recent review discussing biologic proteins and their production, see Ghaderi et al., "Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation," (Darius Ghaderi et al., Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation, 28 BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS 147-176 (2012)). In some embodiments, the proteins include modifications, adducts, and other covalently attached moieties. These modifications, adducts, and moieties include, for example, avidin, streptavidin, biotin, glycans (e.g., N-acetylgalactosamine, galactose, neuraminic acid, N-acetylglucosamine, fucose, mannose, and other monosaccharides), PEG, polyhistidine, FLAGtag, maltose binding protein (MBP), chitin binding protein (CBP), glutathione-S-transferase (GST) myc-epitopes, fluorescent labels, and other dyes, etc. Proteins can be classified based on composition and solubility, and thus include simple proteins, such as globular proteins and fibrous proteins, complex proteins, such as nucleoproteins, glycoproteins, mucoproteins, chromoproteins, phosphoproteins, metalloproteins, and lipoproteins, and derived proteins, such as primary and secondary derived proteins.

[0068] In some exemplary embodiments, the protein may be an antibody, a bispecific antibody, a multispecific antibody, an antibody fragment, a monoclonal antibody, or a combination thereof.

[0069] The term "antibody" as used herein includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, and multimers thereof (e.g., IgM). Each heavy chain contains a heavy chain variable region (herein referred to as HCVR or V H The heavy chain constant region is abbreviated as C H 1. C H 2, and C H Each light chain comprises three domains: a light chain variable region (herein LCVR or V L The light chain constant region comprises one domain (C L 1) is included. H and V L The regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). H and V L is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. In different embodiments of the invention, the FRs of the anti-big-ET-1 antibody (or antigen-binding portion thereof) may be identical to the human germline sequence or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on an alignment analysis of two or more CDRs.

[0070] The term "antibody" as used herein also includes antigen-binding fragments of a complete antibody molecule. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically accessible, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies can be derived from complete antibody molecules using any suitable standard technique, such as, for example, proteolytic digestion, or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable domains and any constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated, for example, by using chemical or molecular biology techniques to place one or more variable and / or constant domains in a suitable configuration, or to introduce codons, to create cysteine ​​residues, to modify, add, or delete amino acids, and for other reasons.

[0071] As used herein, an "antibody fragment" includes a portion of an intact antibody, such as, for example, an antigen-binding or variable region of an antibody. Examples of antibody fragments include, but are not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, scFv fragments, Fv fragments, dsFv diabodies, dAb fragments, Fd' fragments, Fd fragments, and isolated complementarity determining region (CDR) regions, as well as triabodies, tetrabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments. An Fv fragment is a combination of the variable regions of an immunoglobulin heavy and light chains, and an ScFv protein is a recombinant single-chain polypeptide molecule in which immunoglobulin light and heavy chain variable regions are linked by a peptide linker. In some exemplary embodiments, an antibody fragment contains sufficient amino acid sequence of a parent antibody that the fragment binds to the same antigen as the parent antibody, and in some exemplary embodiments, the fragment binds to the antigen with an affinity comparable to that of the parent antibody and / or competes with the parent antibody for binding to the antigen. Antibody fragments may be produced by any means. For example, antibody fragments may be enzymatically or chemically produced by fragmentation of an intact antibody and / or recombinantly produced from a gene encoding a partial antibody sequence. Alternatively or additionally, antibody fragments may be wholly or partially produced synthetically. Antibody fragments may optionally include single chain antibody fragments. Alternatively or additionally, antibody fragments may include multiple chains linked together, for example, by disulfide bonds. Antibody fragments may optionally include multimolecular complexes. Functional antibody fragments typically include at least about 50 amino acids, more typically include at least about 200 amino acids.

[0072] The phrase "bispecific antibodies" includes antibodies that can selectively bind to two or more epitopes. Bispecific antibodies generally comprise two different heavy chains, each of which specifically binds to a different epitope, either on two different molecules (e.g., antigens) or on the same molecule (e.g., on the same antigen). When a bispecific antibody can selectively bind to two different epitopes (a first epitope and a second epitope), the affinity of the first heavy chain for the first epitope will generally be at least one to two or three or four orders of magnitude lower than the affinity of the first heavy chain for the second epitope, or vice versa. The epitopes recognized by a bispecific antibody can be on the same or different targets (e.g., on the same or different proteins). Bispecific antibodies can be made, for example, by combining heavy chains that recognize different epitopes of the same antigen. For example, nucleic acid sequences encoding heavy chain variable sequences that recognize different epitopes of the same antigen can be fused to nucleic acid sequences encoding different heavy chain constant regions, and such sequences can be expressed in a cell that expresses an immunoglobulin light chain.

[0073] A typical bispecific antibody consists of three heavy chain CDRs followed by a C H 1 domain, hinge, C H 2 domain, and C HThey have two heavy chains, each with three domains, and an immunoglobulin light chain that does not confer antigen-binding specificity but can associate with each heavy chain, or can associate with each heavy chain and bind one or more of the epitopes bound by the heavy chain antigen-binding region, or can associate with each heavy chain and allow binding to one or both epitopes of one or both heavy chains. BsAbs can be divided into two major classes, those with an Fc region (IgG-like) and those lacking an Fc region, the latter usually being smaller than IgG and IgG-like bispecific molecules that contain an Fc. IgG-like bsAbs can have different formats, such as, but not limited to, triomabs, knobs into holes IgG (kih IgG), crossmab, ortho-Fab IgG, dual variable domain Ig (DVD-Ig), two-in-one or dual acting Fab (DAF), IgG-single chain Fv (IgG-scFv), or kappa lambda-body. Different non-IgG-like formats include tandem scFvs, diabody formats, single-chain diabodies, tandem diabodies (TandAbs), dual affinity retargeting molecules (DARTs), DART-Fcs, nanobodies, or antibodies produced by dock-and-lock (DNL) technology (Gaowei Fan, Zujian Wang & Mingju Hao, Bispecific antibodies and their applications, 8 JOURNAL OF HEMATOLOGY & ONCOLOGY 130; Dafne Muller & Roland E. Kontermann, Bispecific Antibodies, HANDBOOK OF THERAPEUTIC ANTIBODIES 265-310 (2014)).

[0074] Methods for producing BsAbs include, but are not limited to, quadroma technology based on somatic cell fusion of two different hybridoma cell lines, chemical conjugation involving chemical cross-linking agents, and genetic approaches utilizing recombinant DNA technology. Examples of bsAbs include those disclosed in the following patent applications, which are incorporated herein by reference: U.S. Patent Application No. 12 / 823838, filed June 25, 2010; U.S. Patent Application No. 13 / 488628, filed June 5, 2012; U.S. Patent Application No. 14 / 031075, filed September 19, 2013; U.S. Patent Application No. 14 / 808171, filed July 24, 2015; U.S. Patent Application No. 14 / 808171, filed September 22, 2017; No. 15 / 713574, filed Sep. 22, 2017, U.S. Patent Application No. 15 / 713569, filed Sep. 22, 2017, U.S. Patent Application No. 15 / 386453, filed Dec. 21, 2016, U.S. Patent Application No. 15 / 386443, filed Dec. 21, 2016, U.S. Patent Application No. 15 / 22343, filed July 29, 2016, and U.S. Patent Application No. 15814095, filed Nov. 15, 2017. Low levels of homodimeric impurities may be present at several steps during the manufacture of bispecific antibodies. Detection of such homodimeric impurities may be challenging using intact mass spectrometry due to the low abundance of homodimeric impurities and co-elution of these impurities with the major species when performed using conventional liquid chromatography methods.

[0075] As used herein, a "multispecific antibody" or "Mab" refers to an antibody that has binding specificities for at least two different antigens. Such molecules typically bind only two antigens (i.e., bispecific antibodies, BsAbs), although antibodies with additional specificities, such as trispecific antibodies and KIH trispecifics, can also be addressed by the systems and methods disclosed herein.

[0076] The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. Monoclonal antibodies may be derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, by any means available or known in the art. Monoclonal antibodies useful in the present disclosure can be prepared using a wide variety of techniques known in the art, including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof.

[0077] In some exemplary embodiments, the formulation can include an active agent, and the active agent can be a small molecule. As used herein, the term "small molecule" can refer to a small chemical compound having a molecular weight of less than 1500 kDa.

[0078] In some exemplary embodiments, the formulation may be a protein formulation.

[0079] As used herein, the term "protein formulation" refers to a therapeutic protein that can be formulated with one or more pharma- ceutically acceptable vehicles. In some embodiments, the therapeutic protein can be present in a unit dose amount suitable for administration in a therapeutic regimen.

[0080] In some other embodiments, the formulation may further comprise excipients, including but not limited to buffers, bulking agents, tonicity adjusters, surfactants, solubilizers, and preservatives.Other additional excipients may also be selected based on their function and compatibility with the formulation, for example, as found in Remington: The Science and Practice of Pharmacy. Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995), Hoover, John E., Remington's Pharmaceutical Sciences, (Easton, Pa.: Mack Publishing Co 1975), Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms (New York, NY: Marcel Decker 1980), and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed (Lippincott Williams & Wilkins 1999), all of which are incorporated herein by reference in their entirety.

[0081] In some exemplary embodiments, the formulation may be stable.

[0082] The stability of the formulation may include assessing the chemical stability, physical stability, or functional stability of the active agent. The formulations of the present invention typically exhibit a high level of stability of the active agent.

[0083] With respect to protein formulations, the term "stable" as used herein refers to the protein in the formulation being able to retain an acceptable degree of chemical structure or biological function after storage under exemplary conditions defined herein.A formulation may be stable even if the protein contained therein does not maintain 100% of its chemical structure or biological function after storage for a given time.In certain circumstances, maintaining about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of the protein's structure or function after storage for a specified time may be considered "stable".

[0084] In some exemplary embodiments, the formulations may be used for the treatment, prevention and / or amelioration of a disease or disorder. Exemplary non-limiting diseases and disorders that can be treated and / or prevented by administration of the pharmaceutical formulations of the present invention include infections, respiratory diseases, pain due to any condition associated with neurogenic, neuropathic or nociceptive pain, genetic disorders, congenital disorders, cancer, pulmonary diseases such as herpetic, chronic idiopathic urticaria, scleroderma, hypertrophic scars, Whipple's disease, benign prostatic hyperplasia, mild, moderate or severe asthma, allergic reactions, Kawasaki disease, sickle cell disease, Churg-Strauss syndrome, Graves' disease, pre-eclampsia, Sjogren's syndrome, autoimmune lymphoproliferative syndrome, autoimmune hemolytic anemia, baclofenac, bronchitis, and bronchitis. Rett's esophagitis, autoimmune uveitis, tuberculosis, nephrosis, arthritis including chronic rheumatoid arthritis, inflammatory bowel disease including Crohn's disease and ulcerative colitis, systemic lupus erythematosus, inflammatory diseases, HIV infection, AIDS, LDL apheresis, disorders due to PCSK9 activating mutations (gain of function mutations, "GOF"), disorders due to heterozygous familial hypercholesterolemia (heFH), primary hypercholesterolemia, dyslipidemia, cholestatic liver disease, nephrotic syndrome, hypothyroidism, obesity, atherosclerosis, cardiovascular disease, neurodegenerative diseases, neonatal onset multisystem inflammatory disorder (NOM) ID / CINCA), Muckle-Wells syndrome (MWS), Familial cold autoinflammatory syndrome (FCAS), Familial Mediterranean fever (FMF), Tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), Systemic juvenile idiopathic arthritis (Still's disease), Type 1 diabetes, Type 2 diabetes, Autoimmune disease, Motor neuron disease, Eye disease, Sexually transmitted disease, Tuberculosis, Diseases or conditions ameliorated, inhibited, or reduced by VEGF antagonists, Diseases or conditions ameliorated, inhibited, or reduced by PD-1 inhibitors, Diseases or conditions ameliorated, inhibited, or reduced by interleukin antibodies, Diseases or conditions ameliorated, inhibited, or reduced by NGF antibodies, Diseases or conditions ameliorated, inhibited, or reduced by PCSK9 antibodies, Diseases or conditions ameliorated, inhibited, or reduced by ANGPTL antibodies, Diseases or conditions ameliorated, inhibited, or reduced by activin antibodies, Diseases or conditions ameliorated, inhibited, or reduced by GDF antibodies, Fel dThe diseases or conditions that are ameliorated, inhibited, or reduced by a C1 antibody, a disease or condition that is ameliorated, inhibited, or reduced by a CD antibody, a disease or condition that is ameliorated, inhibited, or reduced by a C5 antibody, or a combination thereof.

[0085] In some exemplary embodiments, the formulation can be administered to a patient. Administration can be via any route. Non-limiting routes of administration include oral, topical, or parenteral. Administration via a certain parenteral route can include introducing the formulation of the present invention into the patient's body through a needle or catheter propelled by a sterile syringe or some other mechanical device, such as a continuous infusion system. The formulation provided by the present invention can be administered using a syringe, injector, pump, or any other device recognized in the art for parenteral administration. The formulation of the present invention can also be administered as an aerosol for absorption in the lungs or nasal cavity. The formulation may be administered for absorption through mucous membranes, such as buccal administration.

[0086] In some exemplary embodiments, human serum albumin can prevent the formation of fatty acid particles. In some exemplary embodiments, human serum albumin can solubilize preformed fatty acid particles. As used herein, "human serum albumin" or "HSA" can include monomeric proteins synthesized in the liver. Human serum albumin can be the major macromolecular component of serum with a concentration of up to 50 g / L, and is constantly in flux between intravascular and extravascular spaces (Angelica M.Merlot, Danuta S.Kalinowski & Des R.Richardson,Unraveling the mysteries of serum albumin-more than just a serum protein,5 FRONTIERS IN PHYSIOLOGY(2014)). Among its various biological activities, HSA can transport low-solubility molecules, including fatty acids, throughout the body (Maja Thim Larsen et al., Albumin-based drug delivery: harnessing nature to cure disease, 4 MOLECULAR AND CELLULAR THERAPIES (2016)). HSA can contain nine different fatty acid binding sites, consisting of three high affinity, one medium affinity, and five low affinity sites (Eileen S. Krenzel, Zhongjing Chen & James A. Hamilton, Correction to Correspondence of Fatty Acid and Drug Binding Sites on Human Serum Albumin: A Two-Dimensional Nuclear Magnetic Resonance Study, 52 BIOCHEMISTRY 2382-2382 (2013)).

[0087] In some exemplary embodiments, the formulation may further include a polysorbate.

[0088] As used herein, "polysorbate" refers to a common excipient used in formulation development to protect antibodies from various physical stresses such as agitation, freeze-thaw processes, and the air / water interface (Emily Ha, Wei Wang & Y. John Wang, Peroxide formation in polysorbate 80 and protein stability, 91 JOURNAL OF PHARMACEUTICAL SCIENCES 2252-2264(2002); Bruce A. Kerwin, Polysorbates 20 and 80 Used in the Formulation of Protein Biotherapeutics: Structure and Degradation Pathways, 97 JOURNAL OF PHARMACEUTICAL SCIENCES 2924-2935(2008); Hanns-Christian Mahler et al., Adsorption Behavior of a Surfactant and a Monoclonal Antibody to Sterilizing-Grade Filters, 99 Journal of Pharmaceutical Sciences 2620-2627 (2010). Polysorbates can include non-ionic amphiphilic surfactants consisting of fatty acid esters of polyoxyethylene-sorbitan, such as a polyoxyethylene sorbitan head group, and either a saturated monolaurate side chain (Polysorbate 20; PS20) or an unsaturated monooleate side chain (Polysorbate 80; PS80). In some exemplary embodiments, polysorbates can be present in the formulation in the range of 0.001% to 1% (weight / volume).Polysorbates can also contain a mixture of various fatty acid chains, for example, polysorbate 80 contains oleic, palmitic, myristic and stearic fatty acids, with the monooleic acid fraction making up about 58% of the polydisperse mixture (Nitin Dixit et al., Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles, 105 JOURNAL OF PHARMACEUTICAL SCIENCES 1657-1666(2016)). Non-limiting examples of polysorbates include polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, and polysorbate-80.

[0089] Polysorbates are prone to autoxidation in a pH- and temperature-dependent manner, and in addition, exposure to UV light can result in instability (Ravuri SkKishore et al., Degradation of Polysorbates 20 and 80: Studies on Thermal Autoxidation and Hydrolysis, 100 JOURNAL OF PHARMACEUTICAL SCIENCES 721-731(2011)), resulting in free fatty acids in solution with sorbitan head groups. The free fatty acids resulting from polysorbates can include any aliphatic fatty acid having 6-20 carbons. Non-limiting examples of free fatty acids include oleic acid, palmitic acid, stearic acid, myristic acid, lauric acid, or combinations thereof.

[0090] In some exemplary embodiments, the fatty acid particles may be at least 5 μm in size. Furthermore, these fatty acid particles may be classified according to their size as visible (>100 μm), sub-visible (<100 μm, which is subdivided into micron (1-100 μm) and sub-micron (100 nm-1000 nm)) and nanometer particles (<100 nm) (Linda Narhi, Jeremy Schmit & Deepak Sharma, Classification of protein aggregates, 101 JOURNAL OF PHARMACEUTICAL SCIENCES 493-498).

[0091] In some exemplary embodiments, the fatty acid particles can be visible particles. Visible particles can be determined by visual inspection.

[0092] In some exemplary embodiments, the fatty acid particles can be sub-visible particles. Sub-visible particles can be monitored by light obscuration methods according to the United States Pharmacopeia (USP).

[0093] In some exemplary embodiments, the fatty acid particles can be formed from polysorbates. In some specific exemplary embodiments, the fatty acid particles can be formed from polysorbates in the presence of a lipase enzyme. As used herein, "lipase" refers to an enzyme that can catalyze the hydrolysis of fats. Lipases can be found in essentially all forms of life, from animals to plants to microorganisms. The mammalian lipase superfamily can consist of seven different classes differentiated by position and substrate specificity. Analysis of CHO-K1 mRNA has found 137 lipases and phospholipases, including variants (Benjamin G. Kremkow et al., CHOgenome.org 2.0: Genome resources and website updates, 10 BIOTECHNOLOGY JOURNAL 931-938 (2015)). The lipase specifically responsible for polysorbate degradation in purified biologic drug products has not been identified, and several may be found, suggesting the influence of the manufacturing process and the biologic itself. Several different lipases can be screened from mammalian, fungal, and bacterial origins available from commercial sources.

[0094] In some exemplary embodiments, fatty acid particles can be detected by Raman spectroscopy. As used herein, the term "Raman spectroscopy" refers to spectroscopy based on Raman scattering. Raman spectroscopy is a method for detecting fatty acid particles in the fingerprint region (2000-400 cm -1), which allows the chemical identification of the analyzed substance by comparison with a database of Raman spectra (CV Raman & KS Krishnan, A New Type of Secondary Radiation, 121 NATURE 501-502 (1928); Zai-Qing Wen, Raman spectroscopy of protein pharmaceuticals, 96 JOURNAL OF PHARMACEUTICAL SCIENCES 2861-2878 (2007)).

[0095] Exemplary embodiments DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The embodiments disclosed herein provide compositions, methods, and systems for rapidly characterizing proteins in a sample.

[0096] As used herein, the terms "include", "includes", and "including" are intended to be open-ended and are understood to mean "comprise", "comprises", and "comprising", respectively.

[0097] In some exemplary embodiments, the disclosure provides a method of preventing or reducing the formation of fatty acid particles in a formulation comprising adding an effective amount of human serum albumin to the formulation.

[0098] In some exemplary embodiments, the disclosure provides a method of solubilizing fatty acid particles in a formulation comprising adding an effective amount of human serum albumin to the formulation.

[0099] In some exemplary embodiments, the disclosure provides a formulation comprising: (i) an active agent; and (ii) human serum albumin.

[0100] In some specific exemplary embodiments, the active pharmaceutical ingredient may be a small molecule. In some other specific exemplary embodiments, the active pharmaceutical ingredient may be a protein. In some exemplary embodiments, the active pharmaceutical ingredient may be a therapeutic protein.

[0101] In some exemplary embodiments, the formulation may comprise an antibody, hi some specific exemplary embodiments, the formulation may comprise an antibody selected from the group consisting of a monoclonal antibody, a polyclonal antibody, an antibody fragment, a bispecific antibody, a multispecific antibody, or a combination thereof.

[0102] In some exemplary embodiments, the formulation can include at least one active agent, hi some specific exemplary embodiments, the formulation can include two active agents.

[0103] In some exemplary embodiments, the formulations can be used in the treatment of a disease or disorder.

[0104] In some exemplary embodiments, the formulations may be used in the prevention of a disease or disorder.

[0105] In some exemplary embodiments, the formulation can be administered to a patient.

[0106] In some specific exemplary embodiments, the formulation may be administered orally to the patient.

[0107] In some exemplary embodiments, the formulation may be administered to the patient via a parenteral route. In some specific embodiments, the formulation may be administered to the patient via an intravenous route. In some specific embodiments, the formulation may be administered to the patient via a subcutaneous route. In some specific embodiments, the formulation may be administered to the patient via an intramuscular route.

[0108] In some exemplary embodiments, the formulation may be a liquid formulation. In some exemplary embodiments, the amount of active agent in the formulation may range from about 0.01 mg / mL to about 600 mg / mL. In some specific embodiments, the amount of active agent in the formulation may range from about 0.01 mg / mL, about 0.02 mg / mL, about 0.03 mg / mL, about 0.04 mg / mL, about 0.05 mg / mL, about 0.06 mg / mL, about 0.07 mg / mL, about 0.08 mg / mL, about 0.09 mg / mL, about 0.1 mg / mL, about 0.2 mg / mL, about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6mg / mL, approximately 0.7mg / mL, approximately 0.8mg / mL, approximately 0.9mg / mL, approximately 1mg / mL, approximately 2mg / mL, approximately 3mg / mL, approximately 4mg / mL, approximately 5mg / mL, approximately 6mg / mL, approximately 7m g / mL, approximately 8 mg / mL, approximately 9 mg / mL, approximately 10 mg / mL, approximately 15 mg / mL, approximately 20 mg / mL, approximately 25 mg / mL, approximately 30 mg / mL, approximately 35 mg / mL, approximately 40 mg / mL, approximately 45 mg / mL, approx. 50 mg / mL, approx. 55 mg / mL, approx. 60 mg / mL, approx. 65 mg / mL, approx. 70 mg / mL, approx. 5 mg / mL, approx. 80 mg / mL, approx. 85 mg / mL, approx. 90 mg / mL, approx. 100 mg / mL, approx. 110 mg / mL, approx. 120 mg / mL, approx. 130 mg / mL, approx. 140 mg / mL, approx. 150 mg / mL, approx. 160 mg / mL, approx. 170 mg / mL, approx. 180 mg / mL, approx. 190 mg / mL mL, about 200 mg / mL, about 225 mg / mL, about 250 mg / mL, about 275 mg / mL, about 300 mg / mL, about 325 mg / mL, about 350 mg / mL, about 375 mg / mL, about 400 mg / mL, about 425 mg / mL, about 450 mg / mL, about 475 mg / mL, about 500 mg / mL, about 525 mg / mL, about 550 mg / mL, about 575 mg / mL, or about 600 mg / mL.

[0109] In some exemplary embodiments, the formulation can form fatty acid particles. In some specific exemplary embodiments, the fatty acid particles can include free fatty acids. In some other specific exemplary embodiments, the ratio of the molecules of free fatty acids to the molecules of human serum albumin is about 6:1 to about 1:1. In some specific exemplary embodiments, the ratio of the molecules of free fatty acids to the molecules of human serum albumin is about 0.5:1, about 0.6:1, about 0.7:1, about 0.8:2, about 0.9:1, about 1:1, about 2:1, about 2:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1. In some specific exemplary embodiments, the fatty acid particles can include oleic acid.

[0110] In some specific exemplary embodiments, the fatty acid particles can include saturated straight chain aliphatic acids. In some other specific exemplary embodiments, the fatty acid particles can include saturated straight chain aliphatic acids having up to 20 carbon atoms. In some other specific specific embodiments, the free fatty acid can include at least one fatty acid selected from ethanoic acid, propanoic acid, butanoic acid, pentanoic acid, hexanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, tetradecanoic acid, pentadecanoic acid, hexadecanoic acid, heptadecanoic acid, octadecanoic acid, nonadecanoic acid, eicosanoic acid, or combinations thereof.

[0111] In some specific exemplary embodiments, the fatty acid particles can include unsaturated straight chain fatty acid.In some specific exemplary embodiments, the fatty acid particles can include unsaturated straight chain fatty acid having up to 20 carbon atoms.In some exemplary embodiments, the free fatty acid particles can include stearidonic acid, linoleic acid, palmitoleic acid, vaccinic acid, paulic acid, ellagic acid, gondoic acid, oleic acid, palmitic acid, stearic acid, myristic acid, lauric acid, arachidonic acid, palmitoleic acid, linoleic acid, arachidonic acid, and combinations thereof.

[0112] In some exemplary embodiments, the concentration of human serum albumin in the formulation may be at least about 2.5 mg / mL. In some specific exemplary embodiments, the concentration of human serum albumin in the formulation is at least about 2.5 mg / mL, at least about 2.6 mg / mL, at least about 2.7 mg / mL, at least about 2.8 mg / mL, at least about 2.9 mg / mL, at least about 3.0 mg / mL, at least about 3.1 mg / mL, at least about 3.2 mg / mL, at least about 3.3 mg / mL, at least about 3.4 mg / mL, at least about 3.5 mg / mL, 3.6 mg / mL, at least about 3.7 mg / mL, at least about 3.8 mg / mL, at least about 3.9 mg / mL, at least about 4.0 mg / mL, at least about 4.1 mg / mL, at least about 4.2 mg / mL, at least about 4.3 mg / mL, at least about 4.4 mg / mL, at least about 4.5 mg / mL, 4.6 mg / mL, at least about 4.7 mg / mL, at least about 4.8 mg / mL, at least about It can be at least about 4.9 mg / mL, at least about 5.0 mg / mL, at least about 5.1 mg / mL, at least about 5.2 mg / mL, at least about 5.3 mg / mL, at least about 5.4 mg / mL, at least about 5.5 mg / mL, 5.6 mg / mL, at least about 5.7 mg / mL, at least about 5.8 mg / mL, at least about 5.9 mg / mL, at least about 6.0 mg / mL, at least about 6.1 mg / mL, at least about 6.2 mg / mL, at least about 6.3 mg / mL, at least about 6.4 mg / mL, at least about 6.5 mg / mL, 6.6 mg / mL, at least about 6.7 mg / mL, at least about 6.8 mg / mL, at least about 6.9 mg / mL, at least about 7.0 mg / mL, at least about 7.1 mg / mL, at least about 7.2 mg / mL, at least about 7.3 mg / mL, at least about 7.4 mg / mL, or at least about 7.5 mg / mL.

[0113] In some exemplary embodiments, human serum albumin in the formulation can reduce the formation of fatty acid particles in the formulation.

[0114] In some exemplary embodiments, the human serum albumin in the formulation is capable of solubilizing the fatty acid particles in the formulation.

[0115] In some exemplary embodiments, human serum albumin in the formulation can bind to the free fatty acids generated by the degradation of polysorbates and sequester them, reducing their effective concentration in solution to levels below the critical micelle concentration.

[0116] In some exemplary embodiments, the human serum albumin in the formulation can function as a fatty acid sink.

[0117] In some exemplary embodiments, human serum albumin in the formulation can eliminate the appearance of visible / subvisible fatty acid particles.

[0118] In some exemplary embodiments, human serum albumin in the formulation may extend the shelf life of the formulation over a formulation that does not contain human serum albumin.

[0119] In some exemplary embodiments, the formulation may further comprise a polysorbate. In some specific embodiments, the polysorbate may be selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, and combinations thereof. In some exemplary embodiments, the concentration of polysorbate in the formulation may be from about 0.001% w / v to about 1% w / v. In some specific embodiments, the concentration of polysorbate in the formulation is about 0.001% w / v, about 0.002% w / v, about 0.003% w / v, about 0.004% w / v, about 0.005% w / v, about 0.006% w / v, about 0.007% w / v, about 0.008% w / v, about 0.009% w / v, about 0.01% w / v, about 0.011% w / v, about 0.012% w / v, about 0.013% w / v, about 0.014% w / v, about 0.015% w / v, about 0.016% w / v, about 0.017% w / v, about 0.018% w / v, about 0.019% w / v, about 0.020% w / v, about 0.021% w / v, about 0.022% w / v, about 0.023% w / v, about 0.024% w / v, about 0.025% w / v, about 0.026% w / v, about 0.027% w / v, about 0.028% w / v, about 0.029% w / v, about 0.030% w / v, about 0.031% w / v, about 0.032% w / v, about 0.033% w / v, about 0.034% w / v, about 0.035% w / v, about 0.036% w / v, about 0.037% w / v, about 0.038% w / v, about 0.039% w / v, about 0.040% w / v, about 0.041% w / v, about 0.0 .016%w / v, approx. 0.017%w / v, approx. 0.018%w / v, approx. 0.019%w / v, approx. 0.02%w / v, approx. 0.021%w / v, approx. 0.022%w / v, approx. 0.023%w / v, approx. 0.024%w / v, approx. 0.0 25%w / v, approx. 0.026%w / v, approx. 0.027%w / v, approx. 0.028%w / v, approx. 0.029%w / v, approx. 0.03%w / v, approx. 0.031%w / v, approx. 0.031%w / v, approx. 0.032%w / v, approx. 0.033 %w / v, approx. 0.034%w / v, approx. 0.035%w / v, approx. 0.036%w / v, approx. 0.037%w / v, approx. 0.038%w / v, approx. 0.039%w / v, approx. 0.04%w / v, approx. 0.041%w / v, approx. 0.042%w / v, approximately 0.043%w / v, approximately 0.044%w / v, approximately 0.045%w / v, approximately 0.046%w / v, approximately 0.047%w / v, approximately 0.048%w / v, approximately 0.049%w / v, approximately 0.05%w / v, approximately 0.051%w / v , about 0.052%w / v, about 0.053%w / v, about 0.054%w / v, about 0.055%w / v, about 0.056%w / v, about 0.057%w / v, about 0.058%w / v, about 0.059%w / v, about 0.06%w / v, about 0.061%w / v, approximately 0.062%w / v, approximately 0.063%w / v, approximately 0.064%w / v, approximately 0.065%w / v, approximately 0.066%w / v, approximately 0.067%w / v, approximately 0.068%w / v, approximately 0.069%w / v, approximately 0.07% w / v, about 0.071% w / v, about 0.072% w / v, about 0.073% w / v, about 0.074% w / v, about 0.075% w / v, about 0.076% w / v, about 0.077% w / v, about 0.078% w / v, about 0.079% w / v, about 0.08% w / v, about 0.081% w / v, about 0.082% w / v, about 0.083% w / v, about 0.084% w / v, about 0.085% w / v, about 0.086% w / v, about 0.087% w / v, about 0.088% w / v, about 0.089% w / v, about 0.09% w / v, about 0.091% w / v, about 0.092% w / v, about 0.093% w / v, about 0.094% w / v, about 0.095% w / v, about 0.096% w / v, about 0.097% w / v, about 0.098% w / v, about 0.099% w / v, about 0.1% w / v, about 0.11% w / v, about 0.12% w / v, about 0.13% w / v, about 0.14% w / v, about 0.15% w / v, about 0.16% w / v, about 0.17% w / v, about 0.18% w / v, about 0.19% w / v, about 0.2% w / v, about 0.21% w / v, about 0.22% w / v, about 0.23% w / v, about 0.24% w / v, about 0.25% w / v, about 0.26% w / v, about 0.27% w / v, about 0.28% w / v, about 0.29% w / v, about 0.3% w / v, about 0.31% w / v, about 0.4% w / v, about 0.41% w / v, about 0.42% w / v, about 0.43% w / v, about 0.44% w / v, about 0.45% w / v, about 0.46% w / v, about 0.47% w / v, about 0.48% w / v, about 0.49% w / v, about 0.5% w / v, about 0.51% w / v, about 0.52% w / v, about 0.53% w / v, about 0.54% w / v, about 0.55% w / v, about 0.56% w / v, about 0.57% w / v, about 0.58% w / v, about 0.59% w / v, about 0.6% w / v, about 0.61% w / v, about 0.62% w / v, about 0.63% w / v, about 0.64% w / v, about 0.65% w / v, about 0.66% w / v, about 0.67% w / v, about 0.68% w / v, about 0.69% w / v, about 0.7% w / v, about 0.71% w / v, about 0.72% w / v, about 0.73% w / v, about 0.74% w / v, about 0.75% w / v, about 0.76% w / v, about 0.77% w / v, about 0.78% w / v, about 0.79% w / v, about 0.8% w / v, about 0.81% w / v, about 0.82% w / v, about 0.83% w / v, about 0.84% w / v, about 0.85% w / v, about 0.It may be about 86% w / v, about 0.87% w / v, about 0.88% w / v, about 0.89% w / v, about 0.9% w / v, about 0.91% w / v, about 0.92% w / v, about 0.93% w / v, about 0.94% w / v, about 0.95% w / v, about 0.96% w / v, about 0.97% w / v, about 0.98% w / v, about 0.99% w / v, or about 1% w / v.

[0120] In some exemplary embodiments, the formulation may further comprise a lipase enzyme.

[0121] In some exemplary embodiments, the formulation may further comprise a polysorbate and a lipase enzyme, which may hydrolyze the polysorbate to form fatty acid particles.

[0122] Various publications, including patents, patent applications, published patent applications, accession numbers, technical articles, and scholarly articles are cited throughout this specification. Each of these references is incorporated herein by reference in its entirety for all purposes.

[0123] The present invention may be more fully understood by reference to the following examples, which should not, however, be construed as limiting the scope of the invention. EXAMPLES

[0124] Materials and Reagent Preparation. All reactions were carried out in an aqueous buffer solution containing 25 mM Tris, pH 7.5, 100 mM KCl, 20 mM CaCl2 (TKC buffer) unless otherwise indicated. Chromobacterium viscosum lipase was purchased from EMD Millipore (Billerica, MA), and lyophilized fatty acid-free human serum albumin (FAF-HSA) and human serum were purchased from Sigma-Aldrich (St. Louis, MO). Ultra-purified polysorbate 20 (PS20) and polysorbate 80 (PS80) were obtained from Croda (Edison, NJ). For experiments with IgG, human lyophilized polyclonal IgG purchased from Sigma-Aldrich (St. Louis, MO) was reconstituted according to the manufacturer's recommendations with 150 mM NaCl and 35 mM Tris pH 8.0 and desalted on a Zeba spin desalting column (Thermo Fisher Scientific) equilibrated with 25 mM Tris, 100 mM KCl, pH 7.5.

[0125] Purification of Reagents. Lyophilized C. viscosum lipase was reconstituted in approximately 1 mL of TKC reaction buffer and purified on a Superdex Increase 200 10 / 300SEC column equilibrated in the same buffer. Purified lipase fractions were pooled and the protein concentration (4.2 mg / mL) was determined by UV chromatography using an extinction coefficient of 0.95. λ=280nm The FAF-HSA concentration was measured on a Nanodrop One C spectrophotometer from Sigma-Aldrich. Aliquots were stored in 10% (v / v) glycerol at -20°C. The FAF-HSA concentration was determined by UV spectroscopy using an extinction coefficient of 0.531. λ=280nm The results were determined using Nanodrop OneC.

[0126] Particle detection by turbidity measurements. A plate-based assay was used to detect the presence of particles by monitoring absorbance at 450 nm over time, typically 2-4 hours. The assay is based on the basic principle of light scattering (evaluation of turbidity) to detect particles larger than approximately 20 nm. Purified lipase was added to TKC buffer containing 0.1% polysorbate 80 at final concentrations ranging from 0.4 to 5 μg / mL. Absorbance was measured at 5-min intervals with intermittent shaking on a Spectra Max 340 plate reader held at 25 °C. A baseline value was established by measuring the absorbance of 0.1% polysorbate 80 without the addition of lipase. Instrument control, data acquisition, and analysis were performed using SoftMax Pro software (version 6.5).

[0127] Several different lipases of mammalian, fungal, and bacterial origin from commercial sources were screened. The selection of bacterial lipase was primarily based on rapid polysorbate hydrolysis and subsequent particle formation, providing a clear advantage for identifying conditions to control particle formation that can take months to years in the setting of biopharmaceutical drug products. In addition, bacterial lipase was amenable to a wider range of solution conditions that strongly affect particle formation. In particular, the presence of potassium is essential, which helps to neutralize the electrostatic repulsion of the acidic head group.

[0128] Example 1. Hydrolysis of polysorbate 80 by Chromobacterium viscosum lipase during particle formation. The formation of particles in solutions containing PS80 can occur through hydrolysis by lipase (Nitin Dixit et al., Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles, 105 JOURNAL OF PHARMACEUTICAL SCIENCES 1657-1666(2016)).

[0129] Particle formation is a multi-step process. First, lipase catalyzes the hydrolysis of PS80 at the fatty acid ester bond to release a sorbitan ring and a fatty acid chain. Second, multiple free fatty acids aggregate to form particles. To test the activity of Chromobacterium viscosum lipase, 0.1% PS80 was incubated with various concentrations of lipase from 0.4 to 5 μg / mL, and the absorbance at 450 nm was monitored over several hours.

[0130] To detect the presence of particles in the solution, the turbidity of the samples was monitored by absorbance spectroscopy. Samples were incubated at 25°C and the absorbance at 450 nm was acquired over a period of 120 min. Different concentrations of lipase were used, ranging from 0 to 1 μg. A sample containing no lipase was used as a control.

[0131] An increase in the signal at 450 nm indicates an increase in solution turbidity due to particle formation. Figure 1 shows that increasing lipase concentration resulted in both an increase in final turbidity and a decrease in the time required to observe the initial increase in dose-dependent response. Additionally, a sample containing no lipase was used as a control (△), which did not increase in turbidity over time and provided a baseline absorbance level.

[0132] Example 2. Identification of the composition of the particles formed 2.1 Particle preparation. Particles were prepared by incubating 2.5 μg / mL lipase with PS80 in TKC buffer for 3 h at room temperature, followed by centrifugation. The supernatant was discarded and the pellet was washed once with buffer and reconstituted by sonication. For particle generation in the presence of IgG, human polyclonal IgG was added to a final concentration of 7.5 mg / mL. The mechanically dispersed pellet was deposited onto a 5 μm polycarbonate membrane filter (RapID; Monmouth Junction, NJ). Raman spectroscopy was performed on the particles using a RapID Single Particle Explorer and a 785 nm monochromatic laser at 100% intensity / 10 s exposure time with a 50× objective to generate a spectrum specific to the sample.

[0133] 2.2 Raman spectroscopy. Raman spectroscopy was used to identify particle constituents after incubating lipase with PS80. This method uses inelastic light scattering to generate an energy spectrum unique to each molecule, which is then compared to a reference library containing fingerprints of various chemical structures. The Raman spectrum of 156 out of 200 particles was identified to be highly similar to that of oleic acid (Figure 2). The black trace as seen in Figure 2 is the internal reference, oleic acid. 1650 cm -1 The peak is directly proportional to the number of C=C bonds in the linear hydrocarbon chain and is therefore a signature of unsaturated oleic acid hydrocarbon chains. Other identified species include lauric acid and palmitic acid, both of which are also degradation products of polysorbates.

[0134] Example 3. Prevention of particle formation by HSA. HSA contains several high and low affinity binding sites for fatty acids and therefore has the potential to act as a fatty acid sink that can inhibit particle formation during polysorbate hydrolysis.To test the effectiveness of HSA to prevent particle formation, 0.1% PS80 was incubated with 0.5 μg lipase at 25° C. in the presence of increasing concentrations of FAF-HSA, and the turbidity of the solution was monitored by measuring the absorbance at 450 nm over 6 hours.

[0135] FIG. 3 shows a graph plotting absorbance at 450 nm as a function of time for various FAF-HSA concentrations. Samples without FAF-HSA (◇) provide an upper limit of absorbance (approximately 0.4 nm). As can be seen in FIG. 3, the effect of HSA on particle appearance is a dose-dependent response, with error bars representing standard error from two replicates. The control sample did not contain FAF-HSA and showed a final absorbance of approximately 0.4 OD after 6 hours. The addition of FAF-HSA resulted in both a decrease in the final absorbance (a decrease in turbidity) and a time delay in the onset of turbidity in a concentration-dependent manner. Notably, samples containing 7.5 mg / mL FAF-HSA did not show any significant absorbance over this period. Similar results were obtained with PS20 instead of PS80 (data not shown).

[0136] Example 4. Partial saturation of fatty acid binding sites prevents HSA from reducing particle formation. To further define the molecular mechanism by which HSA inhibits particle formation, measurements of turbidity changes were performed on solutions containing HSA preincubated with stearic acid in a stoichiometric ratio with three high affinity binding sites. Oleic acid would be a more direct comparison, but the solubility of monounsaturated fatty acids makes it difficult to minimize transfer of free fatty acids into the sample, therefore stearic acid, a saturated molecule with an equal number of carbohydrates, was chosen as an equivalent replacement.

[0137] Stearic acid-loaded HSA (SA-HSA) was prepared by adding 70 mM pure stearic acid (Sigma) in ethanol to FAF-HSA at a 3:1 molar ratio, incubating at room temperature for 30–60 min at 25°C, and then centrifuging at 22,000 rcf for 4 min to pellet unbound stearic acid, followed by addition of 0.5 mg lipase and 0.1% PS80, and monitoring the absorbance at 450 nm for 6 h.

[0138] The plot in Figure 4 shows absorbance at 450 nm as a function of time for various SA-HSA concentrations, where samples without SA-HSA (◯) provide an upper absorbance limit (approximately 0.5) and error bars represent standard error from three replicates.

[0139] Whereas FAF-HSA showed a dose-dependent decrease in turbidity with complete inhibition at 7.5 mg / mL, an increase in turbidity was detected in all samples containing SA-HSA, indicating that particle formation was not inhibited (Figure 4). In addition, the time required for the onset of turbidity was shorter compared to samples containing an equivalent amount of FAF-HSA (Figure 3).

[0140] Example 5. Reducing particle formation in HSA-free antibody preparations The reduction in particle formation appeared to be directly proportional to the concentration of HSA added to the polysorbate / lipase mixture, but it remained possible that any protein could nonspecifically prevent particle formation. To determine whether this effect was specific to HSA or could be a general property of any protein species, we replaced HSA with human polyclonal IgG (N. Leigh Anderson & Norman G. Anderson, The Human Plasma Proteome: History, Character, and Diagnostic Prospects, 1 MOLECULAR & CELLULAR PROTEOMICS 845-867 (2002), the second most abundant circulating serum protein, and monitored the solutions for turbidity over time.

[0141] For experiments with IgG, human polyclonal IgG purchased from Sigma-Aldrich (St. Louis, MO) was reconstituted according to the manufacturer's recommendations in 150 mM NaCl and 35 mM Tris pH 8.0 and desalted on a Zeba spin desalting column (Thermo Fisher Scientific) equilibrated in 25 mM Tris, 100 mM KCl, and pH 7.5.

[0142] To test the specificity of fatty acid particle reduction for HSA, different concentrations of human polyclonal IgG were added to a solution containing 0.5 μg lipase and 0.1% PS80 at 25° C., and the absorbance at 450 nm was monitored for 6 hours.

[0143] A positive control sample containing lipase and PS80 but no IgG (FIG. 5, ◇) was used to provide an upper limit for absorbance (approximately 0.5). A sample containing PS80 and 10 mg / mL IgG but no lipase (red △) was used to provide a negative control showing a baseline absorbance at 450 nm.

[0144] In contrast to the drop in turbidity observed for samples containing FAF-HSA, all samples containing poly-IgG showed a rapid increase in absorbance, indicating that it did not prevent particle formation (Figure 5). Surprisingly, the apparent level of turbidity showed a modest poly-IgG concentration-dependent increase compared to the positive control containing no IgG, but it is difficult to determine whether the increase in absorbance was caused by an increase in particle number or an increase in average particle size. No aggregation was observed in the negative control (Figure 5, red triangles).

[0145] The increase in turbidity is likely due to protein lyophilization. To determine whether the increase in turbidity was due to the way the protein was processed (i.e., lyophilization), two solutions of the mAb were prepared: unmodified from the purified solution state, and a solution state mAb mimicking the manufacturer's lyophilization process used for the poly-IgG preparation. The monoclonal antibody was lyophilized and reconstituted according to the polyclonal IgG manufacturer's instructions to replicate the process, then added to a solution containing 0.5 μg lipase and 0.1% PS80 at 25°C, and the absorbance at 450 nm was monitored for 6 hours. Panel A of Figure 6 shows the monoclonal antibody that was not lyophilized. Panel B of Figure 6 shows the same monoclonal antibody that was lyophilized. The plot shows the absorbance at 450 nm as a function of time for various monoclonal IgG concentrations. The positive control sample (◇), which contains lipase and PS80 but no IgG, provides an upper limit for absorbance (approximately 0.55). The negative control sample (red triangle) containing PS80 and 10 mg / mL IgG but no lipase shows baseline absorbance at 450 nm. The lyophilized material showed a similar increase as poly-IgG, demonstrating that this increase is likely due to the lyophilization process.

[0146] Example 6. Reduction of particle formation in antibody preparations using HSA in vitro To assess whether HSA can reduce particle formation in the presence of polyclonal IgG, an assay with increasing concentrations of polyclonal IgG, HSA, polyclonal IgG, lipase, and PS80 was performed.

[0147] FAF-HSA at 4.5 mg / mL and 7.5 mg / mL were added to samples containing polyclonal IgG, 0.5 μg lipase, and 0.1% PS80 at 25° C., and absorbance at 450 nm was monitored for 6 hours.

[0148] Figure 7 shows plots of absorbance at 450 nm as a function of time for the addition of 4.5 mg / mL FAF-HSA and 7.5 mg / mL FAF-HSA to various polyclonal IgG concentrations. A positive control sample (◇) containing lipase and PS80 but no IgG provides an upper limit for absorbance (approximately 0.5) and error bars represent standard error from two replicates.

[0149] The particle-inhibitory activity of HSA was similar to that observed in the absence of polyclonal IgG (Fig. 3 ), indicating that HSA inhibits particle formation even in the presence of other serum proteins.

[0150] Example 7. Reducing particle formation in antibody preparations using HSA in vivo The rapid lipase-mediated particle formation and detection assay described above demonstrated that HSA can prevent particle formation in vitro. As a first step towards a more relevant in vivo setting, we assessed whether HSA can solubilize pre-existing particles.

[0151] To test the ability of HSA to solubilize preformed particles in solution, particles were prepared (see Materials and Methods) and diluted to obtain a maximum absorbance of approximately 0.5 OD. As shown in Figure 8, preformed particles were incubated with FAF-HSA and the absorbance at 450 nm was monitored for 6 hours (data shown represents 2.5 hours). The positive control sample containing lipase and PS80 but no HSA (Figure 8, ▲) provides an upper limit for absorbance (approximately 0.5). The negative control sample containing PS80 and 7.5 mg / mL HSA but no lipase (Figure 8, red △) shows the baseline absorbance at 450 nm, with error bars representing standard error from three replicates.

[0152] Upon addition of FAF-HSA to solutions containing high levels of fatty acid particles, the turbidity of the solution rapidly decreased, although not all concentrations of FAF-HSA reached baseline levels (Figure 8). The plateau observed at HSA concentrations below 3.5 mg / mL indicates that preformed particles were not completely solubilized. Within the limits of the turbidity assay, HSA concentrations above 5.5 mg / mL were required to completely disrupt preformed particles.

[0153] Example 8. Reduction of particle formation in antibody preparations with HSA in vivo by human serum Experiments similar to those in Example 7 were also performed with human serum, which more closely represents the physiological state. In particular, albumin present in serum binds many different poorly soluble compounds.

[0154] Preformed particles were incubated with normal human serum and the absorbance at 450 nm was monitored for 6 hours (data shown up to 2.5 hours as no further changes were observed) as shown in Figure 9. A positive control sample (△) containing lipase and PS80 but no serum provides an upper limit for absorbance (approximately 0.6). A negative control sample containing PS80 and 21% human serum but no lipase was included (data not shown) and yielded an absorbance of 0.25 OD. Error bars represent standard error from three replicates. Due to the baseline absorbance of human serum, each concentration of serum was also analyzed without lipase, without PS80, or without particles, and the results shown in Figure 9 show background subtracted signals.

[0155] All samples containing serum showed a reduction in turbidity, but only samples with at least 14% serum were able to achieve a substantially particle-free baseline within 1.5 hours. Assuming an upper limit of 50 mg / mL albumin in human serum, this equates to approximately 7.5 mg / mL albumin, which corresponds to the amount of FAF-HSA required to achieve a zero turbidity baseline.

[0156] Thus, a new and potentially beneficial use of human serum albumin in the biopharmaceutical industry has been discovered. HSA can reduce the formation of fatty acid particles, indicating that the inclusion of HSA as an excipient may help extend the shelf life of certain polysorbate-containing drug products. Importantly, HSA can also solubilize particles already present in solution, suggesting that physiological concentrations of HSA, if present, may efficiently and effectively eliminate particles following administration of the drug product.

Claims

1. 23. A method of preventing or reducing the formation of fatty acid particles in a formulation which is capable of forming said fatty acid particles, comprising adding to said formulation an effective amount of human serum albumin.

2. The method of claim 1 , wherein the formulation comprises a polysorbate.

3. The method of claim 1 , wherein the formulation comprises one or more additional proteins.

4. The method of claim 1 , wherein the fatty acid particles comprise free fatty acids.

5. 10. The method of claim 1, wherein the fatty acid particles comprise a free fatty acid selected from the group consisting of oleic acid, palmitic acid, stearic acid, myristic acid, lauric acid, and combinations thereof.

6. 10. The method of claim 1, wherein the concentration of the human serum albumin in the formulation is at least about 5.5 mg / mL.

7. 10. The method of claim 1, wherein the formation of fatty acid particles comprising free fatty acids having from about 6 to about 22 carbon atoms is reduced.

8. The method of claim 1 , wherein the formulation is a parenteral formulation.

9. 10. The method of claim 1, wherein fatty acid particles forming visible or sub-visible particles are reduced.

10. 2. The method of claim 1, wherein one mole of said human serum albumin binds to at least 0.5 moles of free fatty acid contained in said fatty acid particles.

11. The method of claim 1 , wherein the fatty acid particles are at least 10 μm in size.

12. The method of claim 1 , wherein the fatty acid particles are detected by Raman spectroscopy.

13. 3. The method of claim 2, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and combinations thereof.

14. 3. The method of claim 2, wherein the concentration of the polysorbate in the formulation is from about 0.001% w / v to about 1% w / v.

15. The method of claim 3 , wherein the additional protein is an antibody.

16. The method of claim 3 , wherein the additional protein is a monoclonal antibody.

17. The method of claim 3 , wherein the additional protein is a polyclonal antibody.

18. 6. The method of claim 5, wherein the ratio of molecules of free fatty acids to molecules of human serum albumin in the formulation is from about 6:1 to about 1:

1.

19. 1. A method of solubilizing fatty acid particles formed in a formulation, the method comprising adding an effective amount of human serum albumin to said formulation.

20. An active agent; Polysorbate, Human serum albumin and 13. A formulation comprising:

21. The protein formulation of claim 20 , wherein the active agent comprises a monoclonal antibody.

22. The protein formulation of claim 20 , wherein the active agent comprises a polyclonal antibody.

23. The protein formulation of claim 20, wherein the active agent comprises a therapeutic antibody.

24. 21. The protein formulation of claim 20, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or combinations thereof.

25. 21. The protein formulation of claim 20, wherein the formulation further comprises a lipase enzyme.

26. 21. The protein formulation of claim 20, wherein the concentration of said human serum albumin in said protein formulation is at least about 5.5 mg / mL.

27. 21. The protein formulation of claim 20, wherein the formulation is a parenteral formulation.

28. The protein formulation of claim 20, wherein the polysorbate degrades to form fatty acid particles.

29. 29. The protein formulation of claim 28, wherein the fatty acid particles comprise free fatty acids.

30. 30. The protein formulation of claim 29, wherein the free fatty acid is an aliphatic acid having from about 6 to about 22 carbons.

31. 30. The protein formulation of claim 29, wherein the free fatty acid is oleic acid.

32. 30. The protein formulation of claim 29, wherein the free fatty acid is selected from the group consisting of oleic acid, palmitic acid, stearic acid, myristic acid, lauric acid, and combinations thereof.

33. 30. The protein formulation of claim 29, wherein the ratio of molecules of free fatty acids to molecules of human serum albumin in the formulation is from about 6:1 to about 1:

1.

34. 21. The protein formulation of claim 20, wherein the concentration of the polysorbate in the protein formulation is about 0.001% w / v to 1% w / v.

Images